Callan Family Office LLC Buys Shares of 18,161 Koninklijke Philips (NYSE:PHG)

Callan Family Office LLC purchased a new position in Koninklijke Philips (NYSE:PHG - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 18,161 shares of the technology company's stock, valued at approximately $460,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB bought a new position in Koninklijke Philips during the third quarter valued at approximately $54,000. Whipplewood Advisors LLC bought a new stake in Koninklijke Philips in the fourth quarter valued at $55,000. RPg Family Wealth Advisory LLC bought a new stake in Koninklijke Philips in the third quarter valued at $107,000. Allworth Financial LP boosted its holdings in Koninklijke Philips by 24.9% in the fourth quarter. Allworth Financial LP now owns 3,993 shares of the technology company's stock valued at $105,000 after acquiring an additional 797 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its position in Koninklijke Philips by 177.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,489 shares of the technology company's stock valued at $114,000 after buying an additional 2,871 shares during the period. 13.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PHG has been the subject of several recent analyst reports. BNP Paribas raised Koninklijke Philips from a "neutral" rating to an "outperform" rating in a research report on Tuesday, February 25th. UBS Group upgraded Koninklijke Philips from a "neutral" rating to a "buy" rating in a research note on Thursday, February 20th. Finally, StockNews.com upgraded Koninklijke Philips from a "hold" rating to a "buy" rating in a research note on Saturday. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy".

Remove Ads

Koninklijke Philips Trading Down 0.1 %

PHG traded down $0.03 during trading on Wednesday, reaching $26.71. The company had a trading volume of 82,874 shares, compared to its average volume of 873,030. Koninklijke Philips has a 52 week low of $19.10 and a 52 week high of $32.91. The stock has a market cap of $25.10 billion, a P/E ratio of -31.77, a PEG ratio of 0.82 and a beta of 0.78. The business has a 50 day simple moving average of $26.57 and a 200-day simple moving average of $27.92. The company has a quick ratio of 0.74, a current ratio of 1.23 and a debt-to-equity ratio of 0.59.

Koninklijke Philips (NYSE:PHG - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The technology company reported $0.54 EPS for the quarter, missing the consensus estimate of $0.55 by ($0.01). Koninklijke Philips had a negative net margin of 3.88% and a positive return on equity of 10.85%. The firm had revenue of $5.38 billion for the quarter, compared to analysts' expectations of $5.10 billion. On average, equities analysts anticipate that Koninklijke Philips will post 1.63 EPS for the current fiscal year.

Koninklijke Philips Cuts Dividend

The company also recently announced an annual dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 13th will be issued a dividend of $0.886 per share. This represents a dividend yield of 2.9%. The ex-dividend date is Tuesday, May 13th. Koninklijke Philips's dividend payout ratio (DPR) is -89.29%.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.